International team advises Chiesi Farmaceutici on in-licence of Raxone® from Santhera

Contacts

james baillieu module
James Baillieu

Partner
UK

I'm a corporate partner based in London where I advise clients ranging from start-ups to multinationals and venture capital and private equity funds on mergers and acquisitions (and disposals), securities transactions, private equity and venture capital investments/exits, joint ventures and corporate reorganisations.

sally shorthose module
Sally Shorthose

Partner
UK

As one of our firm's most experienced intellectual property partners, specialising in transactional IP matters, I offer a wealth of knowledge to businesses at the cutting edge of research, development and technology, in a variety of sectors for which IP is of prime importance.

International law firm Bird & Bird has advised Chiesi Farmaceutici S.p.A. ("Chiesi") on the in-licence of Raxone® -- an orphan drug used in the treatment of Leber's hereditary optic neuropathy ("LHON"), a rare hereditary eye disease that leads to severe vision loss –- from Swiss group Santhera Pharmaceuticals Holding AG ("Santhera").

Chiesi has in-licensed the rights to Raxone® in LHON and all other ophthalmological indications worldwide except in the US and Canada, where Santhera retains rights. Chiesi also has the option to acquire the Raxone® business following the satisfaction of certain regulatory milestones, including the completion of certain post-authorization measures and the receipt of certain pricing reimbursement approvals. The total consideration for the deal is up to €93 million (approximately CHF 105 million), comprising an upfront cash payment of €44 million (approximately CHF 50 million) together with a number of sales related milestone payments of up to €49 million (approximately CHF 55 million). Closing of the transaction is subject to customary closing conditions including anti-trust approvals.

The multi-office team was led by commercial partner Sally Shorthose and corporate partner James Baillieu in London together with James Pearson (Intellectual Property, London), Sharon O'Donnell, Hannah Fletcher and Megan Curzon (Corporate, London), Philip Hartman and Chelsea Gunning (Employment, The Hague), Richard Eccles and Dániel Arányi (Antitrust, London), Simon Gough (Tax, London) and Alexandre Vuchot and Dora Talvard (Life Sciences Regulatory, Paris). The team acted in close co-operation with the Chiesi in-house team led by Tiziano Toschi together with Federica Pellegrino and Irsida Zefi with Swiss law advice being provided by Manuel Bianchi della Porta and Norbert Schenk of BianchiSchwald.


News & Deals

More News & Deals

Deal

Bird & Bird advises sellers on ASSA ABLOY's acquisition of 9Solutions

Dec 05 2024

Read More

Deal

Bird & Bird advises WIWIN on application for authorisation as a crowdfunding service provider

Dec 05 2024

Read More

Deal

Bird & Bird advises Kindred Education on their sale to private equity investor, Livingbridge

Dec 03 2024

Read More

News

Bird & Bird ATMD acts for Re Sustainability International (Singapore) in its acquisition of G3 Environmental Private Limited

Dec 02 2024

Read More

Deal

Bird & Bird Supported S-Bank in Completing Asset Purchase with Handelsbanken

Dec 02 2024

Read More

Deal

The Prague Bird & Bird transaction team advised Aricoma during acquisition of Clarystone

Dec 02 2024

Read More